Fifty 1 Labs, Inc. Announces Bold Expansion Plan Powered by Nobel Prize Laureate Management Team, Cutting-Edge AI Healthcare Innovation and $350K Leadership Investment
Fifty 1 Labs (OTC: FITY) has announced an ambitious expansion plan targeting a $50 million valuation and leadership in the $320.6 billion functional medicine market. The company's management team, including a Nobel Peace Prize laureate, has demonstrated commitment through a $350,000 personal investment and salary deferrals until reaching the valuation target.
The company's Game Plan includes uplisting to OTCQB by Q1 2026 and eventually to NASDAQ, a $1,000,000 R&D investment in its AI subsidiary Fifty1 AI Labs LLC, and strategic acquisitions in the $5-10 million range. The company focuses on AI-driven drug repurposing and functional medicine, leveraging its proprietary AI platform to identify new therapeutic applications for existing drugs.
Fifty 1 Labs (OTC: FITY) ha annunciato un ambizioso piano di espansione con l'obiettivo di raggiungere una valutazione di 50 milioni di dollari e conquistare una posizione di leadership nel mercato della medicina funzionale da 320,6 miliardi di dollari. Il team di gestione dell'azienda, che include un vincitore del Premio Nobel per la Pace, ha dimostrato il proprio impegno attraverso un investimento personale di 350.000 dollari e la rinuncia temporanea allo stipendio fino al raggiungimento dell'obiettivo di valutazione.
Il piano strategico prevede la quotazione su OTCQB entro il primo trimestre del 2026 e successivamente sul NASDAQ, un investimento di 1.000.000 di dollari in ricerca e sviluppo nella sua controllata AI, Fifty1 AI Labs LLC, e acquisizioni strategiche nell'intervallo tra 5 e 10 milioni di dollari. L'azienda si concentra sul riposizionamento di farmaci tramite intelligenza artificiale e sulla medicina funzionale, sfruttando la sua piattaforma AI proprietaria per identificare nuove applicazioni terapeutiche per farmaci già esistenti.
Fifty 1 Labs (OTC: FITY) ha anunciado un ambicioso plan de expansión con el objetivo de alcanzar una valoración de 50 millones de dólares y liderar el mercado de medicina funcional de 320.6 mil millones de dólares. El equipo directivo de la empresa, que incluye a un laureado con el Premio Nobel de la Paz, ha demostrado su compromiso mediante una inversión personal de 350,000 dólares y la postergación de sus salarios hasta alcanzar la meta de valoración.
El plan de acción contempla la inclusión en OTCQB para el primer trimestre de 2026 y eventualmente en NASDAQ, una inversión de 1,000,000 de dólares en I+D en su subsidiaria de inteligencia artificial Fifty1 AI Labs LLC, y adquisiciones estratégicas en el rango de 5 a 10 millones de dólares. La compañÃa se enfoca en la reutilización de medicamentos impulsada por IA y la medicina funcional, aprovechando su plataforma de IA propietaria para identificar nuevas aplicaciones terapéuticas para medicamentos existentes.
Fifty 1 Labs (OTC: FITY)µç� 5천만 달러 í‰ê°€ì•�ê³� 3,206ì–� 달러 규모ì� 기능ì„� ì˜í•™ 시장ì—서 ì„ ë‘ ìžë¦¬ë¥� 목표ë¡� 하µç” 야심ì°� 확장 계íšì� 발표했습니다. 노벨 í‰í™”ìƒ� 수ìƒìžë¥¼ í¬í•¨í•� 회사 ê²½ì˜ì§„ì€ 35ë§� 달러ì� ê°œì¸ íˆ¬ìžì™€ 목표 í‰ê°€ì•� ë„달 시까지 급여 ìœ ì˜ˆë¥� 통해 í—Œì‹ ì� 보여주었습니ë‹�.
회사ì� ì „ëžµ 계íšì—µç” 2026ë…� 1분기까지 OTCQB ìƒìž¥ê³� ê¶ê·¹ì 으ë¡� NASDAQ ìƒìž¥, AI ìžíšŒì‚¬ì¸ Fifty1 AI Labs LLCì—� 대í•� 100ë§� 달러 연구개발 투ìž, 그리ê³� 500ë§Œ~1,000ë§� 달러 규모ì� ì „ëžµì � ì¸ìˆ˜ê°€ í¬í•¨ë˜ì–´ 있습니다. 회사µç� AI 기반 약물 재활용과 기능ì„� ì˜í•™ì—� 집중하며, ìžì²´ AI 플랫í¼ì„ 활용í•� 기존 약물ì� 새로ìš� 치료 ì‘ìš© 분야ë¥� 발굴합니ë‹�.
Fifty 1 Labs (OTC : FITY) a annoncé un plan d'expansion ambitieux visant une valorisation de 50 millions de dollars et une position de leader sur le marché de la médecine fonctionnelle de 320,6 milliards de dollars. L'équipe de direction de l'entreprise, comprenant un lauréat du Prix Nobel de la Paix, a montré son engagement par un investissement personnel de 350 000 dollars et une renonciation aux salaires jusqu'à l'atteinte de l'objectif de valorisation.
Le plan stratégique prévoit une inscription au OTCQB d'ici le premier trimestre 2026 puis au NASDAQ, un investissement en R&D de 1 000 000 de dollars dans sa filiale d'IA Fifty1 AI Labs LLC, ainsi que des acquisitions stratégiques dans une fourchette de 5 à 10 millions de dollars. L'entreprise se concentre sur le repositionnement de médicaments assisté par IA et la médecine fonctionnelle, en exploitant sa plateforme d'IA propriétaire pour identifier de nouvelles applications thérapeutiques pour des médicaments existants.
Fifty 1 Labs (OTC: FITY) hat einen ehrgeizigen Expansionsplan angekündigt, der eine Bewertung von 50 Millionen US-Dollar und eine Führungsposition im 320,6 Milliarden US-Dollar großen Markt für funktionelle Medizin anstrebt. Das Managementteam des Unternehmens, zu dem ein Friedensnobelpreisträger gehört, hat sein Engagement durch eine persönliche Investition von 350.000 US-Dollar und Gehaltsverzichte bis zum Erreichen des Bewertungsziels unter Beweis gestellt.
Der Geschäftsplan sieht eine Notierung am OTCQB bis zum ersten Quartal 2026 und schließlich am NASDAQ vor, eine Forschung & Entwicklungsinvestition von 1.000.000 US-Dollar in der KI-Tochtergesellschaft Fifty1 AI Labs LLC sowie strategische Übernahmen im Bereich von 5 bis 10 Millionen US-Dollar. Das Unternehmen konzentriert sich auf KI-gesteuerte Wirkstoff-Neuverwendung und funktionelle Medizin und nutzt seine proprietäre KI-Plattform, um neue therapeutische Anwendungen für bestehende Medikamente zu identifizieren.
- None.
- No current revenue or commercial products mentioned
- Significant capital requirements for planned acquisitions ($5-10M range)
- Early-stage company with unproven AI technology
- Ambitious valuation target ($50M) without clear timeline or metrics
Company Targets OTCQB and NASDAQ Uplisting With Breakthroughs in Drug Repurposing, Functional Medicine, and Strategic Acquisitions
SEATTLE, July 08, 2025 (GLOBE NEWSWIRE) -- via IBN -- Fifty 1 Labs, Inc. (), a Nevada-based pioneer in AI-driven drug repurposing and AI-driven functional medicine, today unveiled a transformative Game Plan to achieve a
Game Plan: A Blueprint for Biotech Innovation
FITY's Game Plan is a bold roadmap to reshape healthcare through AI-driven drug repurposing and AI-driven functional medicine, targeting high-growth areas like preventative healthcare in the
- Uplisting to OTCQB and NASDAQ: Secure OTCQB listing by the first quarter of 2026, and NASDAQ Capital Market listing in the next few years, boosting investor visibility and liquidity.
- Strategic Acquisitions: Pursue the acquisition of a biotech startup in the
$5 �10 million range, with additional targeted acquisitions planned to strengthen R&D capabilities and expand market presence. - Digital Engagement: Launch a minimum viable product website by July 24, 2025, and a fully interactive website by July 31, 2025, at to connect with shareholders and customers.
- R&D Leadership: Invest
$1,000,000 in Fifty1 AI Labs LLC to advance AI-driven drug repurposing, aiming for a first discovery by May 2026. - Shareholder Transparency: Host a virtual shareholder conference Q3, 2025, and issue regular press releases to highlight progress, including potential partnerships with industry leaders.
Fifty1 AI Labs LLC: The Heart of AI Innovation
Fifty1 AI Labs LLC, FITY's Delaware-based subsidiary, is the cornerstone of its AI-driven drug repurposing strategy. With a minimum
Elite Management Team: Driving Unprecedented Growth
FITY's leadership team blends scientific excellence, operational expertise, and strategic foresight, propelling the Company toward its ambitious goals. Key members include:
- Paul Arora, Chief Executive Officer: A biotech veteran, Dr. Arora drives FITY's strategic vision, overseeing acquisitions, R&D integration, and execution of the Game Plan's aggressive timelines.
- James Orbinski, Senior Scientist: A physician and global health authority who received the 1999 Nobel Peace Prize on behalf of Medicines Sans Frontiers (Doctors without Borders). Dr. Orbinski brings three decades of experience in humanitarian medicine and strategic leadership. Former International President of Médecins Sans Frontières and Founder of Drugs for Neglected Diseases Initiative (DNDi), Dr. Orbinski enhances operational execution across FITY and Fifty1 AI Labs LLC, aligning global health insights with proven experience developing new and repurposed medicines for large markets, globally.
- Nima Sakian, Chief Medical Officer: A serial entrepreneur and veteran consulting physician, Dr. Sakian drives FITY's vision, identifying acquisitions with aggressive execution on market targeting and drug discovery efforts.
- Richard Robins, Chief Business Development Advisor: Mr. Robins' expertise in securing high-value partnerships, including large enterprise collaborations, fuels FITY's growth in the
$1.55 trillion biotech market (Grand View Research). - Alind Gupta, Chief Technology Officer: An expert in machine learning and causal AI, Dr. Gupta leads the development of Fifty1 AI Labs' AI platform, accelerating drug repurposing and data-driven innovation.
- Professors Edward Mills, Glenn Sammis, Kristian Thorlund (as Scientific Advisors): These distinguished academic scientists, with decades of expertise in pharmacology, clinical research, and data science, guide FITY's R&D toward transformative discoveries.
- Louis Dron, Strategic Advisor: Mr. Dron's strategic acumen strengthens FITY's market positioning and investor relations, critical for uplisting and shareholder value creation.
- Brandon Spikes, Director: A former NFL linebacker and seasoned entrepreneur, Spikes leads 51 LLC, FITY's sports and wellness division, developing AI-informed supplements to capture a share of the
$45 billion sports nutrition market (Allied Market Research). His market influence and business savvy amplify FITY's consumer reach.
This powerhouse team—uniting Spikes' consumer reach, Arora's operational leadership, Sakian's biotech strategy, Orbinski's global health expertise, Robins' partnership acumen, and Gupta's AI innovation—drives FITY's disruptive momentum in AI-driven functional medicine and biotech. Backed by the scientific rigor of Mills, Sammis, and Thorlund, and Dron's strategic oversight, this elite group is executing an aggressive roadmap toward uplisting and market leadership. Their shared vision positions FITY to lead the personalized medicine sector, projected to hit
Leadership Commitment: Salary Deferral and
In a bold display of confidence, FITY's officers and directors are deferring their salaries for two years and until the Company reaches a
AI-Driven Functional Medicine and AI-Driven Drug Repurposing
FITY is seizing the
Join Us for the Virtual Shareholder Teleconference
Join us for the release of Fifty 1 Labs, Inc.'s Virtual Shareholder Teleconference on X on July 28, 2025, at 4:00 PM EST! Hear from our elite management team as they unveil FITY's transformative AI-driven biotech vision and strategic roadmap. Access the teleconference exclusively on our X @Fifty1Labs.
About Fifty 1 Labs, Inc.
Fifty 1 Labs, Inc. (OTC: FITY), a Nevada-based biotech pioneer, is transforming healthcare through AI-driven drug repurposing and functional medicine. Through its subsidiaries, the company delivers innovative, data-driven solutions for preventative healthcare and performance nutrition. Committed to revolutionizing personalized medicine, Fifty 1 Labs is poised to lead the biotech and wellness industries, creating lasting value for shareholders through cutting-edge innovation and strategic growth.
Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements regarding the Company's future financial and operating performance, business strategy, plans, objectives, and expectations regarding future events or performance. These forward-looking statements are based on current expectations, estimates, forecasts, and projections, and involve known and unknown risks, uncertainties, and other factors that may cause actual results, performance, or achievements to differ materially from any future results, performance, or achievements expressed or implied by such forward-looking statements.
Words such as "may," "will," "expect," "anticipate," "intend," "plan," "believe," "seek," "estimate," "could," "would," "continue," "potential," or the negative or other variations thereof and similar expressions are intended to identify forward-looking statements.
Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date they are made. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.
Actual results could differ materially from those anticipated in the forward-looking statements and may be affected by various factors, including but not limited to: the Company's ability to execute its business plans, economic conditions, market demand, competition, regulatory developments, and other risks and uncertainties described in the Company's filings with the Securities and Exchange Commission.
Contact:
Investor Relations
Fifty 1 Labs, Inc.
Email:
Phone: (877) 505-5006
Website:
Wire Service Contact:
IBN
Austin, Texas
512.354.7000 Office
